LRMR Larimar Therapeutics Inc

Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference

Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference

BALA CYNWYD, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company’s management team will present and participate in 1x1 investor meetings at the Leerink Partners Global Healthcare Conference, taking place in Miami Beach, FL from March 10 – 12, 2025.

Details on the presentation can be found below.

Date: Monday, March 10, 2025

Time: 3:40 – 4:10 PM EST

Webcast Link: 

Following the conclusion of the presentation, a replay will be available for 30 days on the “” page of Larimar’s website.

About Larimar Therapeutics

Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: .

Investor Contact:

Joyce Allaire

LifeSci Advisors

(212) 915-2569

Company Contact:

Michael Celano

Chief Financial Officer

(484) 414-2715



EN
03/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Larimar Therapeutics Inc

Wedbush Research
  • Wedbush Research
David Nierengarten ... (+8)
  • David Nierengarten
  • Dennis Pak
  • Dylan Shindler
  • Laura Chico
  • Martin Fan
  • Ritika Das
  • Robert Driscoll
  • Yun Zhong
 PRESS RELEASE

Larimar Therapeutics Provides Nomlabofusp Development Update and Repor...

Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results FDA stated in written correspondence for a START pilot program meeting that it is open to considering skin FXN concentration as a reasonably likely surrogate endpoint in support of an accelerated approvalFDA recommended measuring skin FXN concentrations to support evidence of effectiveness for accelerated approval pathway and acknowledged submitted data appear sufficient to support relationship between increased skin FXN concentrations and relevant tissues such as hea...

 PRESS RELEASE

Larimar Therapeutics to Present at the Leerink Partners Global Healthc...

Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference BALA CYNWYD, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company’s management team will present and participate in 1x1 investor meetings at the Leerink Partners Global Healthcare Conference, taking place in Miami Beach, FL from March 10 – 12, 2025. Details on the presentation can be found below. Date: Monday, March 10, 202...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch